How ModernVivo Reduced Pancreatic Cancer Experimental Development Time by 75%
How ModernVivo Reduced Pancreatic Cancer Experimental Development Time by 75%
Pancreatic cancer has one of the highest mortality rates among all cancer types1,2. Poor prognosis is linked to the aggressive nature of this disease and the presentation of symptoms at later, less treatable stages. Understanding and developing treatments for pancreatic cancer is an area of active research; however, several obstacles make it challenging to study this lethal disease. Firstly, cell lines used for xenograft studies lack the heterogeneity to accurately reflect pancreatic tumors, making it difficult to translate results into real-world applications3. Models often fail to replicate cancer dormancy, which is a significant challenge with pancreatic cancer4. Additional obstacles include the difficulty of replicating the tumor microenvironment5, including the highly immunosuppressive nature of this environment6, and the considerable costs and time required to establish and maintain in vivo models7. Collectively, these complexities have a significant impact on the success of experimental outcomes and can disrupt project timelines.
The Problem
Many in vivo models have emerged to help address the complexities of pancreatic cancer and bridge the gap between the research bench and the clinic3. While advances have helped to improve our understanding of this disease, the volume of available techniques can create an obstacle for researchers during in vivo study design. The vast array of experimental conditions documented in the literature makes it challenging for researchers to identify the exact parameters needed to address their specific research questions. As a result, researchers may spend months reviewing the literature without any assurance of conducting an exhaustive search that accurately identifies their desired parameters. Time spent searching for study parameters causes an initial lag in study progress, and the often incomplete nature of these searches means experiments may fail, extending timelines even further and increasing costs.
The Client's Ask
Faced with the challenge of navigating the vast array of options in the literature, our client reached out to us for assistance in identifying optimal in vivo models for pancreatic cancer. The client needed a way to ensure gold-standard study design that minimized the guesswork and fragmentation associated with manual literature reviews. Our client understood the cost of performing in vivo pancreatic cancer studies and the dramatic cost increases that would be incurred by selecting suboptimal study conditions. We understood our client's needs and aligned with their goal of performing high-quality in vivo experiments to advance our understanding of pancreatic cancer.
ModernVivo's Approach
Our client leveraged the ModernVivo platform to instantly analyze 1271 academic papers and identify the best parameters for their study. The platform allows researchers to both pinpoint precise parameters and gain a broad understanding of the available options without spending hours researching and scanning through materials and methods sections. ModernVivo allows researchers to extract key design parameters and identify designs from the latest, most impactful pancreatic cancer studies. This positions our clients perfectly to move the entire field forward with groundbreaking research, empowering advances that truly make a difference.
75% Reduction in Experimental Development Time
With the ModernVivo approach, our clients achieved a 75% reduction in experimental development time. Importantly, this acceleration did not come at the expense of research quality. On the contrary, the comprehensive nature of ModernVivo-powered searches gave our clients greater confidence in their design and led to more reliable research outcomes in a field where complexities constantly threaten research outcomes. Furthermore, the ModernVivo approach meant our clients eliminated costs associated with lengthy trial-and-error phases that inevitably occur with poorly designed studies.
ModernVivo: Transforming Pancreatic Cancer Research
Pancreatic cancer research faces challenges with replicating tumor environments, refining complex study designs, and high costs. Researchers often spend months on inefficient literature reviews, which extend research timelines and fail to ensure robust study design. ModernVivo empowers biotech companies to streamline R&D processes by optimizing study design and eliminating costly inefficiencies. As research demands increase, ModernVivo’s capabilities will continue to enable faster, more cost-effective breakthroughs, advancing cancer treatment and providing hope to patients facing the poor prognosis of pancreatic cancers.
Ready to simplify your in vivo study design processes while improving research quality? Reach out to ModernVivo for a demo today!
References
1. Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. doi:10.1038/nrdp.2016.22
2. Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022;28(32):4698-4715. doi:10.3748/wjg.v28.i32.4698
3. Salu P, Reindl KM. Advancements in Preclinical Models of Pancreatic Cancer. Pancreas. 2024;53(2):e205-e220. doi:10.1097/MPA.0000000000002277
4. Lin WC, Rajbhandari N, Wagner KU. Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies. Cancer Res. 2014;74(8):2138-2143. doi:10.1158/0008-5472.CAN-13-3437
5. Wishart G, Gupta P, Nisbet A, Schettino G, Velliou E. On the Evaluation of a Novel Hypoxic 3D Pancreatic Cancer Model as a Tool for Radiotherapy Treatment Screening. Cancers (Basel). 2021;13(23):6080. doi:10.3390/cancers13236080
6. Imran KM, Brock RM, Beitel-White N, et al. Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model. Front Immunol. 2024;15:1352821. doi:10.3389/fimmu.2024.1352821
7. Wishart G, Gupta P, Schettino G, Nisbet A, Velliou E. 3d tissue models as tools for radiotherapy screening for pancreatic cancer. Br J Radiol. 2021;94(1120):20201397. doi:10.1259/bjr.20201397
AI Disclosure: Some of this content was generated with assistance from AI tools for copywriting.
.png)
.png)
.png)
.avif)
